Cargando…
Data-driven analysis of a validated risk score for ovarian cancer identifies clinically distinct patterns during follow-up and treatment
BACKGROUND: Ovarian cancer is the eighth most common cancer among women and due to late detection prognosis is poor with an overall 5-year survival of 30–50%. Novel biomarkers are needed to reduce diagnostic surgery and enable detection of early-stage cancer by population screening. We have previous...
Autores principales: | Enroth, Stefan, Ivansson, Emma, Lindberg, Julia Hedlund, Lycke, Maria, Bergman, Jessica, Reneland, Anna, Stålberg, Karin, Sundfeldt, Karin, Gyllensten, Ulf |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9526736/ https://www.ncbi.nlm.nih.gov/pubmed/36196264 http://dx.doi.org/10.1038/s43856-022-00193-6 |
Ejemplares similares
-
Next Generation Plasma Proteomics Identifies High-Precision Biomarker Candidates for Ovarian Cancer
por: Gyllensten, Ulf, et al.
Publicado: (2022) -
High throughput proteomics identifies a high-accuracy 11 plasma protein biomarker signature for ovarian cancer
por: Enroth, Stefan, et al.
Publicado: (2019) -
A two-step strategy for identification of plasma protein biomarkers for endometrial and ovarian cancer
por: Enroth, Stefan, et al.
Publicado: (2018) -
Preoperative Fasting and General Anaesthesia Alter the Plasma Proteome
por: Gyllensten, Ulf, et al.
Publicado: (2020) -
Protein Detection Using the Multiplexed Proximity Extension Assay (PEA) from Plasma and Vaginal Fluid Applied to the Indicating FTA Elute Micro Card™
por: Berggrund, Malin, et al.
Publicado: (2016)